Skip to main content
Equibles
CNSP logo

CNSP · CNS Pharmaceuticals, Inc.

Track CNSP — free

Use CNSP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNSP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.99 +0.14 (+2.87%) At close · Oct 19
Rebalance outlook locked
Market Cap
$7.29M
Shares
1.46M
Volume · Oct 19 5644 Avg daily vol (3M) 6557

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.99 Open$4.85 Day$4.76–5.00 52W close$2.13–9.15 Avg vol 30d5K Short int898 · 0.1% float · 1.0d Short vol43% Last earningsMar 12, 2020 DataJan 2020–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$16.70M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,747.5%
Year over year · more shares
Price change (1Y)
-45.8%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −8%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 41%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Neutral
1-month return −2%
trailing
6-month return +118%
trailing
YTD return −5%
this year
Relative strength +110%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.06% of float · ▼ -69.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Squeeze score 30
low risk · 0–100
Fundamentals
Strong
EPS growth +92%
Y/Y
Free cash flow $-13.8M
Balance sheet $6.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 253%
annualized · 1-yr
Max drawdown −78%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−8% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
41% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.06% of float · ▼ -69.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $5 · 41% Range high $9
vs 200-day avg +8% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CNSP
CNS Pharmaceuticals, Inc.
this stock
$7.29M -5.0% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
19.2%
Net QoQ
+134.8K sh
Top holder
Ikarian Capital, LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
898
Days to cover
1.0d
Change
-2.1K sh
View
Short Volume
Short vol %
43%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$6
As of
Sep 16, 2026
View
Off-Exchange
Off-exchange %
62.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-15.9M
EPS diluted
$-35.75
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 2, 2026
This year
11
View
Exempt Offerings
Offering
$22.5M
Filed
May 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Mar 12, 2020
View

Performance

5D 20D 120D MTD YTD
CNSP -6.7% -2.4% +117.9% -5.9% -5.0%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -5.2% -1.4% +110.2% -6.4% -17.4%
Key facts CIK 1729427 CUSIP 18978H508 Visit website Investor relations